Full-Time

Product Marketing Specialist 2

Maravai LifeSciences

Maravai LifeSciences

51-200 employees

Offers oligonucleotide synthesis and immunohistochemistry

Compensation Overview

$60k - $77k/yr

+ Equity + Bonus

San Diego, CA, USA

In Person

On-site in San Diego, California; local candidates preferred.

Bachelor's

Category
Growth & Marketing (1)
Required Skills
HubSpot
Salesforce
Google AdWords
Data Analysis

Get referred to Maravai LifeSciences

See people who can refer or advise you

Requirements
  • Bachelor's degree in Life Sciences, Molecular Biology, Biochemistry, or a related discipline and 2+ years of experience in product marketing, digital marketing, demand generation, marketing operations, or related marketing functions; or an equivalent combination of education and experience.
  • Experience working within biotechnology, life sciences, diagnostics, pharmaceutical, or other technical B2B industries.
  • Experience executing digital marketing campaigns using CRM, marketing automation, content management, and digital advertising platforms. Salesforce, Account Engagement (Pardot), HubSpot, Marketo, Google Ads, LinkedIn Campaign Manager, or similar platforms preferred.
  • Demonstrated ability to develop marketing content, coordinate campaigns, and support product launches, webinars, trade shows, or scientific events.
  • Strong project management, organizational, communication, and collaboration skills with the ability to manage multiple priorities and meet deadlines.
  • Demonstrated ability to analyze campaign performance and marketing metrics to support continuous improvement.
  • Ability to translate technical or scientific concepts into customer-focused marketing content and communications.
Responsibilities
  • Execute outbound marketing campaigns across email, web, social media, digital advertising, and marketing automation platforms that support product awareness and demand generation.
  • Develop campaign content, messaging, promotional materials, and digital assets that communicate product capabilities and scientific applications.
  • Coordinate product launches, webinars, scientific conferences, trade shows, and marketing campaigns while managing timelines, deliverables, and cross-functional activities.
  • Partner with Product Management, Commercial, Scientific, Creative Services, and Marketing teams to execute integrated marketing initiatives and customer engagement programs.
  • Manage campaign deployment, lead routing, marketing automation workflows, and digital marketing activities using CRM and marketing technology platforms.
  • Monitor and analyze campaign performance, customer engagement, and marketing metrics to recommend improvements that enhance marketing effectiveness.
  • Maintain campaign calendars, marketing assets, project documentation, and reporting to ensure timely execution and operational consistency.
  • Identify and implement process improvements that strengthen campaign execution, marketing operations, and customer engagement.
  • Perform other duties as assigned.

Maravai LifeSciences provides tools and services for life sciences research and bioproduction, including supplying oligonucleotides for PCR, next-generation sequencing (NGS), and gene editing, as well as immunohistochemistry for cancer research, serving academic institutions, biotechnology firms, and pharmaceutical companies. Oligonucleotide synthesis creates short DNA or RNA strands used in PCR, sequencing, and genome editing workflows; immunohistochemistry uses labeled antibodies to detect proteins in tissue samples. It differentiates itself by combining investment and operational support to incubate and scale life science companies while offering essential research tools. Its goal is to catalyze the development of life science companies to advance human health by providing capital, expertise, and essential research tools.

Company Size

51-200

Company Stage

IPO

Headquarters

San Diego, California

Founded

2014

Get referred to Maravai LifeSciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue rose 40.5% to $65.8 million, and guidance increased.
  • Q2 2026 revenue reached $51.4 million, while adjusted EBITDA rose to $8.7 million.
  • Refinancing extended debt maturity to 2032, giving Maravai flexibility for 2026 investments.

What critics are saying

  • Maravai’s February 2025 revenue-restatement scandal exposed internal-control failures and goodwill issues.
  • The August 2025 restructuring cut 25% of staff, risking execution gaps through Q3 2026.
  • COVID CleanCap demand remains volatile; a sustained drop destroys TriLink’s growth engine.

What makes Maravai LifeSciences unique

  • TriLink’s July 20, 2026 CleanCap patents secure dominant mRNA capping IP globally.
  • Cygnus’s mock viral particle technology shields bioprocess testing from direct reagent commoditization.
  • Officinae Bio’s February 24, 2025 acquisition adds AI-enabled mRNA design to TriLink.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Company Equity

Fertility Treatment Support

Family Planning Benefits

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

-2%
Business Wire
Jun 23rd, 2026
Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today anno...

Maravai LifeSciences Holdings, Inc.
Jun 9th, 2026
Maravai LifeSciences Announces Pricing of Secondary Offering of Class A Common Stock by Selling Stockholders

SAN DIEGO, Calif., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of…...

Maravai LifeSciences Holdings, Inc.
Jun 9th, 2026
424B4

The selling stockholders named in this prospectus are offering 20,000,000 shares of our Class A common stock. We are not selling any shares under this prospectus and we will not receive any proceeds from the sale of shares by the selling stockholders.

MarketScreener
Jun 3rd, 2026
Maravai LifeSciences cuts debt to $150M and extends maturity to 2032

Maravai LifeSciences has refinanced its credit agreement, securing a $150 million term loan facility and a $30 million revolving credit facility. The life science reagents provider used the new term loan borrowings and approximately $98.5 million in cash to prepay its existing credit agreement due in October 2027. The transaction reduces Maravai's long-term debt from $242.9 million to $150 million and extends the maturity date to June 2032. Chief Financial Officer Raj Asarpota said the refinancing strengthens the company's financial foundation whilst preserving capital access for strategic priorities and growth initiatives. Maravai provides critical products for drug therapy development, diagnostics and vaccine research, serving major biopharmaceutical, vaccine and cell and gene therapy companies globally.

Associated Press
May 7th, 2026
Maravai LifeSciences raises 2026 guidance after Q1 revenue jumps 40.5% to $65.8M

Maravai LifeSciences, a global provider of life science reagents and services, reported first quarter 2026 revenue of $65.8 million, up 40.5% year-over-year, driven by strong demand in its TriLink business. The company posted a net loss of $6.4 million but achieved adjusted EBITDA of $20.3 million and returned to positive free cash flow, generating $4.2 million. TriLink revenue grew 65% to $47.5 million, including $14.3 million from COVID vaccine programme orders. Excluding COVID-related sales, TriLink base revenue increased 15% year-over-year. Cygnus revenue rose 1.4% to $18.4 million. Following the strong performance, Maravai raised its full-year 2026 guidance, now expecting revenue of $205 million to $215 million and adjusted EBITDA of $30 million to $32 million.